

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 April 2025 (03.04.2025)



(10) International Publication Number
WO 2025/068426 A1

(51) International Patent Classification:

A61K 38/17 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *G01N 33/48* (2006.01)
A61K 45/06 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/077155

(22) International Filing Date:

26 September 2024 (26.09.2024)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2314749.9 26 September 2023 (26.09.2023) GB
2413516.2 13 September 2024 (13.09.2024) GB

(71) Applicant: CYTOVATION ASA [NO/NO]; Solheimsgaten 11, 5058 Bergen (NO).

(72) Inventors: PRESTEGARDEN, Lars; Solheimsgaten 11, 5058 Bergen (NO). BJERKVIK, Rolf; Solheimsgaten 11, 5058 Bergen (NO).

(74) Agent: DZIEGLEWSKA, Hanna; Dehns, St Bride's House, 10 Salisbury Square, London Greater London EC4Y 8JD (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: TREATMENT OF CANCERS ASSOCIATED WITH BETA-CATENIN

(57) Abstract: The present invention provides an oligopeptidic compound, CyPep-1, for use in the treatment of cancers associated with aberrant activation of the Wnt/ β -catenin pathway. The invention also provides a method of treating cancers associated with aberrant activation of the Wnt/ β -catenin pathway, comprising administering the oligopeptidic compound to a subject, optionally together with a second therapeutic agent, and a method of identifying a subject for treatment of a cancer with the oligopeptidic compound comprising determining, in a sample obtained from a subject, the presence of a biomarker indicative of an activated Wnt/ β -catenin pathway. It has been discovered that CyPep-1, previously shown to preferentially target and disrupt the plasma membrane of cancer cells, also acts by inhibiting the Wnt/ β -catenin pathway. This dual therapeutic effect is of particular therapeutic interest since the use of CyPep-1 may affect, in particular, cancers that display aberrant activation of the Wnt/ β -catenin signalling pathway. This compound has a distinct dual mechanism of action promoting immune activation and reversing immune exclusion.

WO 2025/068426 A1